Kura Oncology, Inc. (KURA) Stock Score, Valuation & Financial Research

Kura Oncology, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KURA

Kura Oncology, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 10.67. These figures are a research snapshot, not a buy or sell recommendation.

What Kura Oncology, Inc. does

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Kura Oncology is a clinical-stage biopharmaceutical company that generates revenue primarily through collaboration agreements involving the development and commercialization of its oncology product candidates. Additionally, the company has begun generating product revenue from the commercial sale of its first approved product, Ziftomenib (KOMZIFTI).

Products and services

  • The company's pipeline consists of small molecule product candidates designed to target cancer signaling pathways, including Ziftomenib (KOMZIFTI), which is indicated for the treatment of relapsed or refractory NPM1-mutated acute myeloid leukemia.

Brands and product families

  • KOMZIFTI (ziftomenib) — The company's first approved product for the treatment of relapsed or refractory NPM1-mutated acute myeloid leukemia. Source

Annual revenue by business

  • Collaboration Revenue: USD 65,350,000 · 96.84% calculated revenue share (period 2025-12-31) Source
  • Product: USD 2,132,000 · 3.16% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Pharmaceutical and biotechnology companies (collaboration partners); Healthcare providers and hospitals (for commercial product sales).

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the supply of active pharmaceutical ingredients and drug products; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Kyowa Kirin Co., Ltd. — A strategic collaboration and license agreement for the development and commercialization of ziftomenib. Source

Business strengths to evaluate

  • Precision medicine approach supported by extensive translational research Source
  • Pipeline of small molecule candidates targeting significant unmet medical needs Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and suppliers Source
  • Significant regulatory and clinical development risks Source

Sources: Company research source · Collaboration Revenue

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KURA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 10.67
Market capitalization:
947.22M (currency not supplied)
Revenue:
USD 77.23M
Net income:
USD -296.78M
Free cash flow:
USD -70.7M
Cash:
USD 70.24M
Total debt:
USD 24.46M
EPS:
USD -3.37

What stands out

  • Reported year-over-year revenue growth is +14.4%.
  • Free cash flow is USD -70.7M, negative for the stored period.
  • The balance sheet shows USD 70.24M of cash versus USD 24.46M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -91.5% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -384.3% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 45.79M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KURA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can KURA maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can KURA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is KURA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for KURA to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of KURA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research KURA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.